Shilpa Medicare Ltd
NSE:SHILPAMED

Watchlist Manager
Shilpa Medicare Ltd Logo
Shilpa Medicare Ltd
NSE:SHILPAMED
Watchlist
Price: 887 INR -0.16% Market Closed
Market Cap: 86.7B INR
Have any thoughts about
Shilpa Medicare Ltd?
Write Note

Shilpa Medicare Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shilpa Medicare Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Shilpa Medicare Ltd
NSE:SHILPAMED
Operating Income
â‚ą1.6B
CAGR 3-Years
22%
CAGR 5-Years
13%
CAGR 10-Years
5%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Operating Income
â‚ą65B
CAGR 3-Years
28%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Operating Income
â‚ą56.2B
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
14%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Operating Income
â‚ą112.5B
CAGR 3-Years
13%
CAGR 5-Years
17%
CAGR 10-Years
4%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Operating Income
â‚ą27.8B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
10%
M
Mankind Pharma Ltd
NSE:MANKIND
Operating Income
â‚ą21.5B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shilpa Medicare Ltd
Glance View

Market Cap
86.7B INR
Industry
Pharmaceuticals

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

SHILPAMED Intrinsic Value
1 241.53 INR
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Shilpa Medicare Ltd's Operating Income?
Operating Income
1.6B INR

Based on the financial report for Jun 30, 2024, Shilpa Medicare Ltd's Operating Income amounts to 1.6B INR.

What is Shilpa Medicare Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
5%

Over the last year, the Operating Income growth was 442%. The average annual Operating Income growth rates for Shilpa Medicare Ltd have been 22% over the past three years , 13% over the past five years , and 5% over the past ten years .

Back to Top